The BRAF pathway is also considered to play an important role in HCC; although it may not be the key to carcinogenesis, HCC patients with BRAF mutations may have more aggressive tumors and stronger resistance to TKI treatment. This evidence concerns the gene BRAF and hepatocellular carcinoma.